Evonik Evonik

X

Find Parsaclisib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Parsaclisib
Also known as: 1426698-88-5, Incb050465, Parsaclisib [inn], Parsaclisib [usan], Incb-050465, Os7097575k
Molecular Formula
C20H22ClFN6O2
Molecular Weight
432.9  g/mol
InChI Key
ZQPDJCIXJHUERQ-QWRGUYRKSA-N
FDA UNII
OS7097575K

Parsaclisib is an inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.
1 2D Structure

Parsaclisib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one
2.1.2 InChI
InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1
2.1.3 InChI Key
ZQPDJCIXJHUERQ-QWRGUYRKSA-N
2.1.4 Canonical SMILES
CCOC1=C(C(=C(C=C1C(C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)C4CC(=O)NC4
2.1.5 Isomeric SMILES
CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4
2.2 Other Identifiers
2.2.1 UNII
OS7097575K
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (4r)-4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

2. 2-pyrrolidinone, 4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4r)-

3. Incb050465

2.3.2 Depositor-Supplied Synonyms

1. 1426698-88-5

2. Incb050465

3. Parsaclisib [inn]

4. Parsaclisib [usan]

5. Incb-050465

6. Os7097575k

7. (4r)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one

8. (4r)-4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

9. 2-pyrrolidinone, 4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4r)-

10. Parsaclisib (usan/inn)

11. Parsaclisib [usan:inn]

12. Incb050465 Free Base

13. Parsaclisib [who-dd]

14. Incb-050465 Free Base

15. Parsaclisib (incb050465)

16. Chembl4297615

17. Schembl14736228

18. Unii-os7097575k

19. Bdbm272573

20. Ex-a2638

21. Who 10589

22. Db14867

23. Ac-36916

24. Us10065963, 32c

25. Hy-109068

26. Cs-0033435

27. D11437

28. (r)-4-(3-((s)-1-(4-amino-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

2.4 Create Date
2015-02-02
3 Chemical and Physical Properties
Molecular Weight 432.9 g/mol
Molecular Formula C20H22ClFN6O2
XLogP32.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count5
Exact Mass432.1476798 g/mol
Monoisotopic Mass432.1476798 g/mol
Topological Polar Surface Area108 Ų
Heavy Atom Count30
Formal Charge0
Complexity632
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of mature B-cell malignancies


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY